Phosphoenolpyruvate depletion mediates both growth arrest and drug tolerance of Mycobacterium tuberculosis in hypoxia | PNAS
Mycobacterium tuberculosis clinical isolates carry mutational signatures of host immune environments | Science Advances
Phosphoenolpyruvate depletion mediates both growth arrest and drug tolerance of Mycobacterium tuberculosis in hypoxia | PNAS
Integration of TB-LAM and Xpert MTB/RIF (Xpert) testing to improve TB case detection and shorten time to treatment initiation among People Living with HIV (PLHIV) in Harare City, Zimbabwe
Multidrug-resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis – TB DIAH
Weakening Tuberculosis Bacteria's Defenses May Speed Treatment and Thwart Drug Resistance | Newsroom | Weill Cornell Medicine
Assay Procedure for the MTB/RIF Test. Two volumes of sample treatment... | Download Scientific Diagram
Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A modeling study | PLOS Medicine
Juliana Furtado Gets the Lower-link VPP Treatment - Mountain Bike Press Release - Vital MTB
Reduced treatment delays for people with drug-resistant TB and HIV co-infection through decentralised care and rapid Xpert MTB/RIF test | aidsmap
Mind the gap – Managing tuberculosis across the disease spectrum - eBioMedicine
Xpert MTB/RIF Ultra Is Highly Sensitive for the Diagnosis of Tuberculosis Lymphadenitis in a High-HIV Setting | Journal of Clinical Microbiology
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis | NEJM
Microorganisms | Free Full-Text | Diabetes-Associated Susceptibility to Tuberculosis: Contribution of Hyperglycemia vs. Dyslipidemia
Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing? - The Lancet Infectious Diseases
MRIGlobal - As a partner in the Mycobacterium tuberculosis (Mtb) Quality Assessment Program (TBQA), we evaluate technologies, support research, and study trends that support improved response and treatment. Read more in our
Funding Opportunities | Vanderbilt Tuberculosis Center
4.2 Adult and adolescent algorithms | MSF Medical Guidelines
Frontiers | Mycobacterium tuberculosis functional genetic diversity, altered drug sensitivity, and precision medicine
New agents for the treatment of drug-resistant Mycobacterium tuberculosis - ScienceDirect
Frontiers | Molecular Diagnosis of Drug-Resistant Tuberculosis; A Literature Review
Comprehensive gene profiling, molecular tumor board (mtb) and artificial intelligence in the diagnosis and treatment of patients with rare adult cancers – EJP RD – European Joint Programme on Rare Diseases
Cepheid | Cepheid | TB Drug-Resistance Testing | Xpert MTB-XDR
Early tuberculosis treatment monitoring by Xpert® MTB/RIF | European Respiratory Society
Figure 5 - Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia - Volume 22, Number 3—March 2016 - Emerging Infectious Diseases journal - CDC
